
enleofen bio
Boehringer Ingelheim And Enleofen Bio Strike Billion-Dollar Deal
Enleofen Bio will receive more than US$1 billion in earnout payments from Boehringer Ingelheim’s acquisition of worldwide exclusive rights to its preclinical interleukin-11 platform.

The Cause Of Fibrosis Found Hiding In Plain Sight
A new class of anti-fibrotic drugs may soon be in the pipeline as researchers in Singapore identify the molecule responsible for causing fibrosis in organs.